Literature DB >> 34256394

Fibroblast activation protein inhibitor (FAPi) positive tumour fraction on PET/CT correlates with Ki-67 in liver metastases of neuroendocrine tumours.

Barbara Kreppel1, Maria Angeles Gonzalez-Carmona2, Georg Feldmann3, Jim Küppers1, Euy Sung Moon4, Milka Marinova5, Ralph Alexander Bundschuh1, Glen Kristiansen6, Markus Essler7, Frank Roesch4, Florian Christoph Gaertner1.   

Abstract

AIM: Gallium-68-labelled inhibitors of the fibroblast activation protein (FAPi) enable positron emission tomography/computed tomography (PET/CT) imaging of fibroblast activation. We evaluated if [68Ga]Ga-DATA5m.SA.FAPi PET/CT is related to Ki-67 as a marker of tumour aggressiveness in patients with liver metastases of NET.
METHODS: Thirteen patients with liver metastases of a histologically confirmed NET who underwent PET/CT with [68Ga]Ga-DATA5m.SA.FAPi, [18F]FDG and [68Ga]Ga-DOTA-TOC were retrospectively analyzed. PET-positive liver tumour volumes were segmented for calculation of volume, SUVmax and PET-positive tumour fraction (TF). PET parameters were correlated with Ki-67.
RESULTS: FDGSUVmax correlated positively (rho = 0.543, p < 0.05) and DOTATOCSUVmax correlated negatively (rho = -0.618, p < 0.05) with Ki-67, the correlation coefficients were in the moderate range. There was no significant correlation between FAPiSUVmax and Ki-67 (rho = 0.382, p > 0.05). FAPiTF correlated positively (rho = 0.770, p < 0.01) and DOTATOCTF correlated negatively (rho = -0.828, p < 0.01) with Ki-67, both significantly with high correlation coefficients. FDGTF also correlated significantly with Ki-67, with a moderate correlation coefficient (rho = 0.524, p < 0.05). The ratio FAPiVOL:DOTATOCVOL showed a significant and strong correlation with Ki-67 (rho = 0.808, p < 0.01).
CONCLUSION: The ratio FAPiVOL:DOTATOCVOL might serve as a clinical parameter for the assessment of dedifferentiation and aggressiveness of liver metastases in patients with NET. [68Ga]Ga-DATA5m.SA.FAPi might hold potential for identification of high-risk patients. Further studies are warranted to evaluate its prognostic significance in comparison to [18F]FDG in patients with NET. Thieme. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34256394     DOI: 10.1055/a-1521-8604

Source DB:  PubMed          Journal:  Nuklearmedizin        ISSN: 0029-5566            Impact factor:   1.379


  3 in total

1.  Associations between Normal Organs and Tumor Burden in Patients Imaged with Fibroblast Activation Protein Inhibitor-Directed Positron Emission Tomography.

Authors:  Aleksander Kosmala; Sebastian E Serfling; Niklas Dreher; Thomas Lindner; Andreas Schirbel; Constantin Lapa; Takahiro Higuchi; Andreas K Buck; Alexander Weich; Rudolf A Werner
Journal:  Cancers (Basel)       Date:  2022-05-25       Impact factor: 6.575

2.  Head-to-Head Comparison of Fibroblast Activation Protein Inhibitors (FAPI) Radiotracers versus [18F]F-FDG in Oncology: A Systematic Review.

Authors:  Giorgio Treglia; Barbara Muoio; Hessamoddin Roustaei; Zahra Kiamanesh; Kamran Aryana; Ramin Sadeghi
Journal:  Int J Mol Sci       Date:  2021-10-17       Impact factor: 5.923

3.  From Automated Synthesis to In Vivo Application in Multiple Types of Cancer-Clinical Results with [68Ga]Ga-DATA5m.SA.FAPi.

Authors:  Lukas Greifenstein; Carsten S Kramer; Euy Sung Moon; Frank Rösch; Andre Klega; Christian Landvogt; Corinna Müller; Richard P Baum
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.